-
公开(公告)号：US20140271692A1
公开(公告)日：2014-09-18
申请号：US14138421
申请日：2013-12-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Harpreet SINGH , Steffen WALTER , Toni WEINSCHENK , Norbert HILF , Oliver SCHOOR , Claudia TRAUTWEIN
CPC classification number: A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
Abstract translation: 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。
-
112.发明公开公开(公告)号：US20230340046A1
公开(公告)日：2023-10-26
申请号：US18314878
申请日：2023-05-10
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61K35/17 , C07K7/06 , C07K14/54
CPC classification number: C07K14/4748 , A61P35/00 , A61K39/001102 , A61K39/0011 , C07K14/7051 , C07K14/70539 , C07K16/2818 , C07K16/30 , C12N5/0638 , C12N15/1062 , C12N15/115 , G01N33/57492 , A61K35/17 , C07K7/06 , C07K14/5434 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2501/50 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
113.发明公开公开(公告)号：US20230287069A1
公开(公告)日：2023-09-14
申请号：US17819470
申请日：2022-08-12
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61K35/17 , G01N33/574 , C07K16/30 , C12N5/0783 , A61K39/00 , C07K14/725 , A61P35/00 , C12N15/10 , C07K7/06 , C07K14/54 , C07K14/74 , C12N15/115 , C07K16/28
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , A61K39/001102 , A61P35/00 , C07K7/06 , C07K14/5434 , C07K14/7051 , C07K14/70539 , C07K16/30 , C07K16/2818 , C12N5/0638 , C12N15/115 , C12N15/1062 , G01N33/57492 , A61K38/00 , A61K2039/572 , C07K2319/00 , C12N2501/50
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
114.发明公开公开(公告)号：US20230285462A1
公开(公告)日：2023-09-14
申请号：US18185653
申请日：2023-03-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
115.发明公开公开(公告)号：US20230279066A1
公开(公告)日：2023-09-07
申请号：US18297076
申请日：2023-04-07
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61K35/17 , C07K7/06 , C07K14/54
CPC classification number: C07K14/4748 , A61P35/00 , A61K39/001102 , A61K39/0011 , C07K14/7051 , C07K14/70539 , C07K16/2818 , C07K16/30 , C12N5/0638 , C12N15/1062 , C12N15/115 , G01N33/57492 , A61K35/17 , C07K7/06 , C07K14/5434 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2501/50 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
116.发明公开公开(公告)号：US20230265158A1
公开(公告)日：2023-08-24
申请号：US18054566
申请日：2022-11-11
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , C12N9/64 , G01N33/566 , C12N5/0783 , C07K14/47 , G01N33/569 , C12Q1/6886 , A61K45/06 , A61K39/00 , A01N37/46 , A61K38/17 , C07K16/28 , A61K38/06 , C07K14/00 , C07K16/30 , A61K38/08 , C07K16/18 , G01N33/50 , C07K7/02 , C07K7/06 , C07K14/725 , A61K38/00
CPC classification number: C07K14/70539 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/30 , C07K16/2833 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12Q1/6886 , G01N33/505 , G01N33/566 , G01N33/5088 , G01N33/56972 , G01N33/56977 , A61K38/00 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , A61K2039/5158 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2501/998 , C12N2502/11 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N2333/47 , G01N2333/7051 , G01N2333/70503 , G01N2333/70539 , G01N2500/10
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
117.发明公开公开(公告)号：US20230242604A1
公开(公告)日：2023-08-03
申请号：US18170154
申请日：2023-02-16
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61K35/17 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12Q1/6886
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12Q1/6886 , G16B25/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
118.发明公开公开(公告)号：US20230241110A1
公开(公告)日：2023-08-03
申请号：US18164418
申请日：2023-02-03
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
119.发明公开公开(公告)号：US20230235016A1
公开(公告)日：2023-07-27
申请号：US18052824
申请日：2022-11-04
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , A61K38/06 , C12N9/64 , C12N5/0783 , C07K16/30 , C07K14/47 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/00 , C07K7/06 , C07K7/02 , G01N33/50 , G01N33/566 , C07K16/18 , A61K38/08 , C07K14/725 , G01N33/569 , A61K38/17 , C12Q1/6886 , A01N37/46
CPC classification number: C07K14/70539 , A61K38/06 , C12N9/6491 , C12N5/0636 , C07K16/30 , C07K14/4748 , A61K39/0011 , C07K16/2833 , A61K45/06 , C07K14/001 , C07K7/06 , C07K7/02 , G01N33/505 , G01N33/566 , G01N33/5088 , A61K39/0005 , C07K16/18 , C07K14/47 , C12N5/0638 , A61K38/08 , C07K14/7051 , G01N33/56972 , C07K14/4702 , A61K38/1774 , C12Q1/6886 , G01N33/56977 , A01N37/46 , C07K2317/34 , C12Q2600/106 , C12Q2600/158 , G01N2333/7051 , A61K2039/54 , G01N2333/70539 , C07K2317/31 , C07K2317/24 , G01N2333/70503 , C07K2319/00 , C07K2319/40 , C12N2502/11 , A61K2039/572 , G01N2333/47 , C12N2501/998 , C12Y304/24 , A61K2039/57 , A61K2039/585 , A61K38/00
Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
120.发明公开公开(公告)号：US20230233612A1
公开(公告)日：2023-07-27
申请号：US18176678
申请日：2023-03-01
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
623
records
(took 0.022 seconds)
